Tag Archive for: oncology

The start of the school year is often a time for reflection and renewal. It’s a time when many people think about their future prospects—the perfect opportunity to explore continuing education options! To mark this occasion, we’d like to introduce you to one of our 198 university diplomas (DU) and inter-university diplomas (DIU): the DU in “From Normal Cells to Tumor Cells.” To do so, we sat down with the two co-directors of this program, Ms. Szablewski and Mr. Ramirez. Here’s the interview.

 

Ms. Szablewski, Mr. Ramirez, good morning. Could you please briefly introduce yourselves?

VS: I am Dr. Vanessa Szablewski, MCU-PH in Pathological Anatomy and Cytology at the Montpellier University Hospital. I specialize in hematopathology and ENT pathology. For my research, I am affiliated withINSERM UMR 1058, “Pathogenesis and Control of Chronic and Emerging Infections.” My research focuses on the role of human papillomaviruses (HPVs) in cancers of the head and neck region.

JMR: I have held a Ph.D. in Biological Sciences for Health since 2005. After completing my dissertation, I conducted several postdoctoral fellowships abroad—in Washington, D.C., in the United States; at the Geneva University Hospital in Switzerland; and at the CIC (Centro de Investigación contra el Cáncer) in Spain—before finally returning to France to join the IRMB in Montpellier. In 2015, I was hired as an associate professor at the Montpellier-Nîmes Faculty of Medicine in Professor Thierry Lavabre-Bertrand’s department, where I teach histology and cell biology. In 2019, Vanessa and I created the first website featuring virtual slides that combines three disciplines: anatomy, pathological anatomy, and histology.

 

You are both in charge of the university certificate program “From Normal Cells to Tumor Cells.” What motivated you to create this program?

JMR: Histology and pathological anatomy are two closely related disciplines; it seemed to me that it is essential for a researcher in the field of health to be familiar not only with histology (the study of tissues) but also with pathological tissues.

 

Who is this training primarily intended for? How long does it last?

VS: This program is intended for all researchers working in the field of oncology, as well as those who wish to learn about human tissues and the diseases associated with them. It is also intended for physicians who wish to pursue a career in research or for oncologists who wish to acquire a solid foundation in scientific oncology. The program spans one academic year, but classes are held between February and June. The curriculum includes 52 hours of instruction, divided into 6 modules.

 

What added value will future graduates gain from this program? Does it open up new career paths for enrolled students?

JMR: The primary benefits are, first and foremost, the acquisition of new fundamental skills that will better equip future physicians or researchers in the field of oncology to perform their duties. Second, for all future physicians, the ability to better interpret medical findings provided by a physician specializing in pathological anatomy.

 

On Thursday, January 27, 2022, Dr. Catherine Alix-Panabières received the prestigious Savchuk Prize at the 15th Oncology Biennial for her work on “liquid biopsies.” A look back at 23 years of research in the field of oncology.

A career focused on the development of liquid biopsy

Dr. Alix-Panabières, director of the Rare Human Circulating Cells (CCRH) laboratory at Montpellier University Hospital, has been dedicated to her research for 23 years. Coined by her in 2010 in collaboration with her German colleague, Professor Klaus Pantel of Hamburg, the term “liquid biopsy”—which complements tissue biopsy—refers to a blood test that is performed repeatedly throughout a patient’s treatment.

 

A noninvasive procedure

A liquid biopsy provides access to circulating cells or particles released by the primary tumor or metastases. The advantage? It offers the ability to repeatedly study tumors located in inaccessible areas, all while being noninvasive. After the blood sample is collected, it provides information on the tumor’s progression and, consequently, the effectiveness of treatment.

His research focuses on three fundamental aspects:

  1. Understanding the biology of the tumor and its prognosis.
  2. Technology: Dr. Alix-Panabières is working on a patent related to this new technique for detecting circulating tumor cells.
  3. A translational clinical study. Liquid biopsy makes it possible to tailor treatment to each patient’s stage, particularly when initiating treatment.

We extend our heartfelt congratulations to Dr. Catherine Alix-Pananières on winning this award!